AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27422360 — intervention group
Group type: EXPERIMENTAL
Intervention: External stapled excision (StEx)
Number of subjects: 28
Study 27422360 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision (SxEx)
Number of subjects: 28
Study 25344383 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (30 mg per day)
Number of subjects: 21
Study 25344383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20974089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (n=6), attended classes once a week and practiced 10 minutes daily for 15 weeks
Number of subjects: 11
Study 20974089 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5), received no intervention
Number of subjects: 11
Study 20974089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (n=6)
Number of subjects: 11
Study 20974089 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 11
Study 21088457 — intervention group
Group type: COMPARATOR
Intervention: Open Bankart repair
Number of subjects: 64
Study 21088457 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 64
Study 18223016 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS at 10 Hz (subthreshold)
Number of subjects: 46
Study 18223016 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS at 10 Hz
Number of subjects: 46
Study 15807740 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adapalene gel (0.1%)
Number of subjects: 55
Study 15807740 — intervention group
Group type: COMPARATOR
Intervention: Topical metronidazole gel (0.75%)
Number of subjects: 55
Study 12911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Estrogen Receptor Modulators (SERMs)
Number of subjects: 0
Study 12911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (Clomid)
Number of subjects: 0
Study 12911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 12911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 0
Study 12911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 11091218 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (1 microg/kg and 5 microg/kg)
Number of subjects: 8
Study 11091218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11091218 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg/kg b.i.d)
Number of subjects: 8
Study 9248767 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg racemic nicardipine (conventional preparation)
Number of subjects: 8
Study 9248767 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg racemic nicardipine (conventional preparation)
Number of subjects: 8
Study 9248767 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg sustained-release nicardipine
Number of subjects: 8
Study 8287938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amiloride, administered four times daily for two six month periods
Number of subjects: 23
Study 8287938 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered four times daily for two six month periods
Number of subjects: 23
Study 8287938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amiloride
Number of subjects: 23
Study 8287938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3826597 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (rectal administration)
Number of subjects: 247
Study 3826597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 29872288 — intervention group
Group type: EXPERIMENTAL
Intervention: GB 6.25 μg BID
Number of subjects: 202
Study 29872288 — intervention group
Group type: EXPERIMENTAL
Intervention: GB 12.5 μg BID
Number of subjects: 202
Study 29872288 — intervention group
Group type: EXPERIMENTAL
Intervention: GB 25 μg BID
Number of subjects: 202
Study 29872288 — intervention group
Group type: EXPERIMENTAL
Intervention: GB 50 μg BID
Number of subjects: 202
Study 29872288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 28387543 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-AP 10 mg extended release
Number of subjects: 10
Study 28387543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26147790 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish indicator set
Number of subjects: 200
Study 26147790 — intervention group
Group type: EXPERIMENTAL
Intervention: French indicator set
Number of subjects: 200
Study 26147790 — intervention group
Group type: EXPERIMENTAL
Intervention: German indicator set
Number of subjects: 200
Study 26147790 — intervention group
Group type: COMPARATOR
Intervention: Gold standard assessment
Number of subjects: 200
Study 24264227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (gluten-free products with purified oats)
Number of subjects: 0
Study 24264227 — intervention group
Group type: COMPARATOR
Intervention: Diet B (gluten-free products with placebo)
Number of subjects: 0
Study 21466389 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) 5/80 mg
Number of subjects: 0
Study 21466389 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 0
Study 21466389 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 0
Study 18543485 — intervention group
Group type: EXPERIMENTAL
Intervention: Huanglan Granule (HLG) - one dosage per day, containing milkvetch root, isatis root and basket fern, each 30 g
Number of subjects: 60
Study 18543485 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin - 0.2 g, three times per day
Number of subjects: 60
Study 18543485 — intervention group
Group type: EXPERIMENTAL
Intervention: Huanglan Granule (HLG)
Number of subjects: 60
Study 16864837 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic generalized epilepsy
Number of subjects: 0
Study 16864837 — intervention group
Group type: COMPARATOR
Intervention: Localization-related epilepsy
Number of subjects: 0
Study 12482764 — intervention group
Group type: EXPERIMENTAL
Intervention: Single caffeine dose (6 mg/kg) 60 min before exercise and placebo 45 min into exercise (CP)
Number of subjects: 9
Study 12482764 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided caffeine dose (3 mg/kg) 60 min before and 45 min into exercise (CC)
Number of subjects: 9
Study 12482764 — intervention group
Group type: COMPARATOR
Intervention: Placebo 60 min before and 45 min into exercise (PP)
Number of subjects: 9
Study 12482764 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided caffeine dose (3 mg/kg) (CC)
Number of subjects: 9
Study 12482764 — intervention group
Group type: EXPERIMENTAL
Intervention: Single caffeine dose (6 mg/kg) (CP)
Number of subjects: 9
Study 12482764 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine doses (CP and CC)
Number of subjects: 9
Study 10685094 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable pulse Er:YAG laser
Number of subjects: 21
Study 10685094 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser resurfacing
Number of subjects: 21
Study 9332313 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1; CP020)
Number of subjects: 57
Study 9332313 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine (DFO)
Number of subjects: 57
Study 8437152 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 30
Study 8437152 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 31517512 — intervention group
Group type: EXPERIMENTAL
Intervention: REDCHiP intervention
Number of subjects: 43
Study 31843831 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Clubs programme
Number of subjects: 1008
Study 28884132 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine-replacement
Number of subjects: 120
Study 28884132 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine-continuous
Number of subjects: 120
Study 27037633 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form of ASSIST comprising three items (past‐3‐month frequency of use, urge to use, and whether others have expressed concern for use)
Number of subjects: 2599
Study 27037633 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of tobacco, alcohol, and cannabis items
Number of subjects: 2599
Study 24812543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish (Atlantic salmon) three times per week from September to February
Number of subjects: 95
Study 24812543 — intervention group
Group type: COMPARATOR
Intervention: Control group (alternative meal such as chicken, pork, beef with the same nutritional value) three times per week from September to February
Number of subjects: 95
Study 24812543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 95
Study 24812543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish group vitamin D status
Number of subjects: 95
Study 24812543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 95
Study 24812543 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV
Number of subjects: 95
Study 22992610 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp protocol
Number of subjects: 100
Study 22992610 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp protocol
Number of subjects: 100
Study 20502757 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-septal sutures using a novel device
Number of subjects: 64
Study 20502757 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing with a tampon
Number of subjects: 64
Study 18284032 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 400 mg per day
Number of subjects: 30
Study 18284032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg per day
Number of subjects: 30
Study 18284032 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium gluconate 400 mg per day)
Number of subjects: 30
Study 16269645 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 26
Study 16269645 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 26
Study 16269645 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI reversal in tPA patients
Number of subjects: 26
Study 16269645 — intervention group
Group type: COMPARATOR
Intervention: Acute DWI region that infarcted
Number of subjects: 26
Study 11865843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid dipstick assay for the detection of Salmonella typhi‐specific IgM antibodies
Number of subjects: 127
Study 10218094 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic bladder
Number of subjects: 0
Study 10218094 — intervention group
Group type: COMPARATOR
Intervention: Normal bladder
Number of subjects: 0
Study 10218094 — intervention group
Group type: COMPARATOR
Intervention: Obstructed bladder
Number of subjects: 0
Study 7793871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (50 mg/kg once daily for 10 +/- 3 days)
Number of subjects: 30
Study 7793871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg once daily for 10 +/- 3 days)
Number of subjects: 30
Study 2228655 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital and postdischarge nursing interventions
Number of subjects: 67
Study 2228655 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 67
Study 345173 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation treatment
Number of subjects: 0
Study 31656179 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with targeted sedation using processed electroencephalogram monitoring
Number of subjects: 218
Study 31656179 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without processed electroencephalogram monitoring
Number of subjects: 218
Study 31656179 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with targeted sedation
Number of subjects: 218
Study 31656179 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 218
Study 29468508 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 0.25% bupivacaine plus tizanidine 6 mg capsule (Group SC+T)
Number of subjects: 60
Study 29468508 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 0.25% bupivacaine (Group SC)
Number of subjects: 60
Study 29468508 — intervention group
Group type: COMPARATOR
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 0.9% saline plus oral placebo (Group C)
Number of subjects: 60
Study 26743709 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular telephone-based care and three home visits from a health professional over 2 years
Number of subjects: 410
Study 26743709 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no regular contact with health professionals)
Number of subjects: 410
Study 25439973 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary parent education program
Number of subjects: 42
Study 25439973 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 42
Study 21901320 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (0.5 mg/kg)
Number of subjects: 0
Study 21901320 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (1.0 mg/kg)
Number of subjects: 0
Study 21901320 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg)
Number of subjects: 0
Study 21901320 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.3 mg)
Number of subjects: 0
Study 21901320 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg)
Number of subjects: 0
Study 18843179 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval
Number of subjects: 30
Study 18843179 — intervention group
Group type: COMPARATOR
Intervention: Standard rehearsal
Number of subjects: 30
Study 16736148 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma trochanteric nail
Number of subjects: 112
Study 16736148 — intervention group
Group type: COMPARATOR
Intervention: ACE trochanteric nail
Number of subjects: 112
Study 15173845 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 40
Study 15173845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11120963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 120 mg by injection (group 1 and group 2)
Number of subjects: 30
Study 11120963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 240 mg by infusion (group 3)
Number of subjects: 30
Study 9766341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study 8137478 — intervention group
Group type: COMPARATOR
Intervention: 4'-epidoxorubicin (70 mg) alone (group A)
Number of subjects: 36
Study 8137478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol emulsion with 4'-epidoxorubicin (70 mg) (group B)
Number of subjects: 36
Study 2530761 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg/day (titrated between 10 and 50mg/day)
Number of subjects: 111
Study 2530761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 2530761 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 111
Study 1094970 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 54
Study 1094970 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 54
Study 1094970 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy with midline incision
Number of subjects: 54
Study 1094970 — intervention group
Group type: COMPARATOR
Intervention: Small bowel bypass without cholecystectomy
Number of subjects: 54
Study 31593088 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial blockers (BB)
Number of subjects: 200
Study 31593088 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen bronchial tubes (DLBT)
Number of subjects: 200
Study 31593088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 28903738 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-PA (goal-setting and behavioral education workshops with mentor support via telephone)
Number of subjects: 100
Study 28903738 — intervention group
Group type: COMPARATOR
Intervention: CO-PA (standard education workshops and Physical Activity Liaison contact via telephone)
Number of subjects: 100
Study 26031368 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine combined with oxaliplatin (CAPOX) followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab.
Number of subjects: 0
Study 26031368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (part of the intervention group).
Number of subjects: 0
Study 26031368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 0
Study 24378824 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary calprotectin concentrations in bladder cancer patients (522.3 ng/ml)
Number of subjects: 181
Study 24378824 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin concentrations in low grade tumors (351.9 ng/ml)
Number of subjects: 181
Study 24378824 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for urinary calprotectin
Number of subjects: 181
Study 21899798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis (BB-12®)
Number of subjects: 211
Study 21899798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei (L. casei 431®)
Number of subjects: 211
Study 21899798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 19283996 — intervention group
Group type: EXPERIMENTAL
Intervention: Verhaltenstraining fur Schulanfanger (intervention)
Number of subjects: 88
Study 19283996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 17126335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiplex/AP gel treatment (treated group)
Number of subjects: 37
Study 17126335 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 37
Study 15709663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiotemporal blind source separation (BSS) algorithm
Number of subjects: 0
Study 15709663 — intervention group
Group type: COMPARATOR
Intervention: Independent component analysis (ICA) method
Number of subjects: 0
Study 15709663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiotemporal BSS algorithm
Number of subjects: 0
Study 15709663 — intervention group
Group type: COMPARATOR
Intervention: ICA method
Number of subjects: 0
Study 12505246 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents (those who participated in the trial)
Number of subjects: 112528
Study 12505246 — intervention group
Group type: EXPERIMENTAL
Intervention: Willing respondents (those who agreed to participate)
Number of subjects: 112528
Study 12505246 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible respondents (those who completed a run-in phase and were randomized)
Number of subjects: 112528
Study 12505246 — intervention group
Group type: EXPERIMENTAL
Intervention: Men completing a run-in and randomized into PHS
Number of subjects: 112528
Study 10592423 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral fluids with diazepam
Number of subjects: 50
Study 10592423 — intervention group
Group type: COMPARATOR
Intervention: Parenteral fluids without diazepam (control group)
Number of subjects: 50
Study 7856522 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational angioplasty
Number of subjects: 100
Study 7856522 — intervention group
Group type: COMPARATOR
Intervention: Conventional angioplasty
Number of subjects: 100
Study 1765205 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 pessaries (2.5 mg) 1‐2 a day
Number of subjects: 125
Study 1765205 — intervention group
Group type: COMPARATOR
Intervention: PGE2 (0.5 mg) in a viscous intracervical gel once daily
Number of subjects: 125
Study 6812230 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% amino acids with 3% glycerol
Number of subjects: 2
Study 6812230 — intervention group
Group type: COMPARATOR
Intervention: 3% amino acids
Number of subjects: 2
Study 31780429 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage (twice per day in the morning and evening)
Number of subjects: 84
Study 31780429 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 84
Study 30611335 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 53
Study 30611335 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 53
Study 30611335 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 53
Study 28176487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam Immediate-Release Tablets (8 mg/tablet)
Number of subjects: 30
Study 25813356 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto servo-ventilation (ASV)
Number of subjects: 0
Study 25813356 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0
Study 25813356 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV manual (PSmin 6)
Number of subjects: 0
Study 23562228 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic training
Number of subjects: 15
Study 23562228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21093035 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ormocer (ORM)
Number of subjects: 20
Study 21093035 — intervention group
Group type: COMPARATOR
Intervention: Commercial mixed dimethacrylate‐ormocer‐based matrix (Admira (ADR))
Number of subjects: 20
Study 21093035 — intervention group
Group type: COMPARATOR
Intervention: Commercial dimethacrylate‐based matrix composites (Grandio (GRD) and Premise (PRE))
Number of subjects: 20
Study 19205956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical activity intervention (8-week programme, 24 sessions)
Number of subjects: 16
Study 19205956 — intervention group
Group type: COMPARATOR
Intervention: Vocational rehabilitation class (control group, 8-week programme, 24 sessions)
Number of subjects: 16
Study 17687149 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bolus CPT‐11 plus FU plus LV
Number of subjects: 1264